Otsuka has announced the launch of its new Meptin Swinghaler procaterol hydrochloride DPI for the treatment of asthma and COPD in Japan as of July 2, 2014. The Meptin Swinghaler was approved in Japan in February 2014. According to the company, Japan has over 1 million asthma patients, and Meptin's share of the Japanese market is over 50%. The Swinghaler, … [Read more...] about Otsuka launches Meptin Swinghaler DPI in Japan
Business
Vectura announces new partnership for generic fluticasone propionate DPI
Vectura has announced a new US partnership for its VR506, which it describes as "an ICS for the treatment of asthma" and as "clinical stage asthma monotherapy delivered using Vectura’s proprietary technology." Elsewhere, the company has identified the product as a fluticasone propionate DPI. According to Vectura, it has signed the new agreement for development … [Read more...] about Vectura announces new partnership for generic fluticasone propionate DPI
Respiratory Technology Group at WIMR gets grant for development of inhaled vaccines
The Australian Research Council (ARC) has awarded a 3-year, $482,738 linkage grant titled "One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung" to members of the Respiratory Technology team at the Woolcock Institute of Medical Research (WIMR) and Evonik Industries. The partnership aims to develop a new, low-cost technology … [Read more...] about Respiratory Technology Group at WIMR gets grant for development of inhaled vaccines
Verona Pharma halts development of inhaled antitussive
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial. The trial evaluated the efficacy of a single dose of VRP700 in 20 idiopathic pulmonary fibrosis patients with severe chronic cough. … [Read more...] about Verona Pharma halts development of inhaled antitussive
Teva, Perrigo, and Catalent reach settlement in ProAir HFA case
Under the terms of a newly reached settlement, Perrigo and Catalent will be able to market limited quantities of their generic version of Teva's Proair HFA albuterol MDI starting in December 2016. Beginning in July 2018, the companies will be licensed to market unlimited quantities of the product. No other details of the settlement were disclosed. Teva had filed … [Read more...] about Teva, Perrigo, and Catalent reach settlement in ProAir HFA case
Bespak adding inhaler manufacturing facilities
According to Consort Medical's financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m facility for the manufacture of a DPI currently known as DEV610 to the existing 19,300 sq m facilities at its King's Lynn, UK site. The nicotine device will be fully … [Read more...] about Bespak adding inhaler manufacturing facilities
Discovery Labs gets $1.9 million for Aerosurf development
Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already underway. The company had previously received $580,000 of the Fast Track Small Business Innovation Research (SBIR) grant, which it used for development of its … [Read more...] about Discovery Labs gets $1.9 million for Aerosurf development
AstraZeneca licenses inhaled interferon beta from Synairgen
AstraZeneca has paid $7.25 million up-front with potential milestone payments of up to $225 million for a global licence from Synairgen for its SNG001 inhaled interferon beta for the treatment of viral respiratory tract infections in severe asthma patients. The agreement also includes royalties "ranging from single-digit up to mid-teens" for commercial sales, and … [Read more...] about AstraZeneca licenses inhaled interferon beta from Synairgen
Grifols makes $5 million milestone payment to Aradigm as Pulmaquin Phase 3 trial begins
Aradigm has received a $5 million milestone payment from Grifols as the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis gets underway, the company announced. In May 2013, Grifols paid $25 million upfront to license Aradigm's inhaled ciprofloxacin … [Read more...] about Grifols makes $5 million milestone payment to Aradigm as Pulmaquin Phase 3 trial begins
MVIC to develop inhaled drug for Chinese pharma company
According to Swedish CRO Medicon Valley Inhalation Consortium (MVIC), the organization has entered into a 2-year, €1.6 million contract with a Chinese company to develop an inhaled generic drug for the treatment of asthma and COPD. MVIC will develop a new inhalation product for asthma and COPD. The new contract brings MVIC's total orders over the past year to €2.5 … [Read more...] about MVIC to develop inhaled drug for Chinese pharma company